Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on February 12, 2019. The company is developing the Orion Visual Cortical Prosthesis, an implanted device intended to provide artificial vision to individuals blind from various causes. The report details the completion of enrollment for the sixth subject in the Early Feasibility Study (EFS) at Baylor College of Medicine in January 2019.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial progress and risk factor updates.
Material Changes and Clinical Updates
- Enrollment Milestone: The sixth subject in the Orion EFS was implanted in January 2019 with no adverse events noted during the surgery.
- Device Performance Issue: In January 2019, the first subject (implanted January 2018) exhibited higher impedance levels on 11 of 60 electrodes, resulting in a loss of phosphene generation for those electrodes. The subject continues to use the device, and no safety risks are currently known.
- Adverse Event History: In June 2018, a subject experienced a seizure during video stimulation algorithm evaluation. The event resolved quickly with medication, and the subject continued in the study.
Risks, Contingencies, and Management Commentary
Management updated risk factors regarding potential side effects and device failures that could delay regulatory approval or limit commercialization. Key risks include:
- Device Defects: The company is investigating the root cause of the higher impedance levels, considering manufacturing defects, handling damage, or material issues. While accelerated aging tests showed no failures up to 6.5 years, there is no assurance the issue is isolated.
- Clinical Trial Risks: Positive results in the limited six-subject feasibility study may not translate to pivotal trials. Potential adverse events range from intracranial hemorrhage and infection to psychiatric events and device malfunction.
- Regulatory and Commercial Impact: Undesirable side effects or device failures could lead to trial suspension, recruitment difficulties, or the need for design changes, potentially causing material harm to the business.
Investor Verification Checklist
- Verify the root cause analysis results for the higher impedance levels observed in the first subject.
- Confirm whether the impedance issue is isolated to the first subject or present in the other five enrolled subjects.
- Monitor the safety committee's review of the June 2018 seizure event and its long-term implications for the stimulation algorithm.
- Review the company's cash runway and burn rate in subsequent filings, as this 8-K contains no financial data.
- Assess the timeline for transitioning from the Early Feasibility Study to a pivotal clinical trial.